论文部分内容阅读
本文采用１５３ＳＭ－ＥＤＴＭＰ作为内照射药物治疗多发性骨转移癌，取得较满意效果，减轻了患者癌性骨痛所致痛苦，提高了生活质量。３８例患者，其中肺癌１２例，乳腺癌１２例，鼻咽癌７例，左眼恶性黑色素瘤１例，其它癌６例。经放射性核素显像、Ｘ线及ＣＴ证实为骨转移癌。单发灶５／１８例（１３．１％），多发灶３３／３８例（８６．９％）。结果：完全缓解１０／３８例（２６．３％），部分缓解２２／３８例（５７．９％），无效６／３８例（１５．８％），总有效率８４．２％。反复多次连续用药效果好。毒副作用少，偶有一过性白细胞／血小板减低，或轻微消化道反应。１５３ＳＭ－ＥＤＴＭＰ治疗骨转移癌值得推广，配合综合治疗疗效更好。
In this paper, 153SM-EDTMP as internal medicine for the treatment of multiple bone metastases, to obtain more satisfactory results, reduce pain caused by cancer pain and improve the quality of life. 38 patients, including 12 cases of lung cancer, breast cancer in 12 cases, nasopharyngeal carcinoma in 7 cases, 1 case of left eye malignant melanoma, 6 cases of other cancers. Radionuclide imaging, X-ray and CT confirmed as bone metastases. Single stove 5/18 cases (13.1%), multiple stoves 33/38 cases (86.9%). Results: Completely relieved 10/38 cases (26.3%), partial remission 22/38 cases (57.9%), ineffective 6/38 cases (15.8%), total effective rate 84.2%. Repeatedly repeated multiple drug effect. Less toxic side effects, occasionally transient leukopenia / thrombocytopenia, or mild digestive tract reactions. 153SM-EDTMP treatment of bone metastases is worth promoting, with better comprehensive treatment.